Showing 1921-1930 of 6037 results for "".
- Neurophth Therapeutics' Treatment of Leber's Hereditary Optic Neuropathy Gene Therapy NR082 Granted Orphan Drug Designation by EMAhttps://modernod.com/news/neurophth-therapeutics-treatment-of-lebers-hereditary-optic-neuropathy-gene-therapy-nr082-granted-orphan-drug-designation-by-ema/2480605/Neurophth Therapeutics announced that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) granted the orphan drug designation (ODD) for the company's leading gene therapy drug candidate, NR082 (rAAV2-ND4), for the treatment of Leber's hereditary opt
- Nicox Appoints Doug Hubatsch as new Chief Scientific Officer to lead Clinical and Nonclinical Developmenthttps://modernod.com/news/nicox-appoints-doug-hubatsch-as-new-chief-scientific-officer-to-lead-clinical-and-nonclinical-development/2480509/Nicox SA announced the appointment of Doug Hubatsch to lead all of the company’s nonclinical and clinical development activities. As Chief Scientific Officer, Mr. Hubatsch will be responsible for setting the research and development st
- Coburn Technologies Launches Waterless Lens Deblocking System and Alloy Recovery Systemhttps://modernod.com/news/coburn-technologies-launches-waterless-lens-deblocking-system-and-alloy-recovery-system/2479494/Coburn Technologies has officially launched the Reimagine Campaign to announce new technology advancements in lens processing. Coburn has developed a completely waterless lens deblocking system and a first-of-its-kind alloy recovery system for labs that use alloy for lens processing.
- ARVO Women’s Leadership Development Program Welcomes Class of 2021https://modernod.com/news/arvo-womens-leadership-development-program-welcomes-class-of-2021/2479483/The Association for Research in Vision and Ophthalmology (ARVO) recognized the 2021 class of its Women’s Leadership Development Program (WLDP). The program, provided through the support of Aerie Pharmaceuticals, is an interactive, year-long learning experience focused on leadership skill developm
- Lenz Therapeutics Debuts with $47 Million Series A Financinghttps://modernod.com/news/lenz-therapeutics-debuts-with-47-million-series-a-financing/2479301/Lenz Therapeutics debuted today with a $47 million Series A financing to move the company’s lead asset, an eyedrop formulation of aceclidine, toward an NDA submission for the treatment of presbyopia. The financing was
- Essilor Receives FDA Breakthrough Device Designation for Essilor Stellest Spectacle Lenshttps://modernod.com/news/essilor-receives-fda-breakthrough-device-designation-for-essilor-stellest-specticle-lens/2479220/Essilor announced that the FDA has granted Breakthrough Device designation to its Essilor Stellest spectacle lens, the company’s new generation lens developed to correct myopia and slow down the progression of myopia in children. The designation of the Essilor’s Stellest spectacle lens as
- Ophthalmic World Leaders Announces Development and Networking Program for Executives Seeking Corporate Board Positionshttps://modernod.com/news/ophthalmic-world-leaders-announces-development-and-networking-program-for-executives-seeking-corporate-board-positions/2479130/Ophthalmic World Leaders (OWL) has announced its inaugural “Get-On-Board with OWL” program. Primarily aimed at executive-level women and underrepresented communities, this new offering will help attendees develop the skills and connections required to secure board positions in a rapid
- PYC’s Lead Investigational Drug, VP-001, Demonstrates Another Key Functional Improvement in Patient-Derived Modelshttps://modernod.com/news/pycs-lead-investigational-drug-vp-001-demonstrates-another-key-functional-improvement-in-patient-derived-models/2478930/PYC Therapeutics announced that the company’s lead investigational drug, VP-001, for the treatment of RP11 has restored function of the retinal pigment epithelium (RPE), the target cells for the therapy, in patient-derived models of the disease. “This result builds further conviction in VP
- FCI Ophthalmics Announces Availability of LacriJet for Monocanalicular Nasolacrimal Intubationhttps://modernod.com/news/fci-ophthalmics-announces-availability-of-lacrijet-for-monocanalicular-nasolacrimal-intubation/2478907/FCI Ophthalmics announced the launch of the LacriJet in the United States. It is the first, self-retaining monocanalicular nasolacrimal intubation preloaded on a single use injector, according to FCI Ophthalmics. LacriJet consists of a single use injector handpiece into which a silicone tu
- Nidek Launches B-scan Denoising Software With Deep Learning to Enhance OCT Retinal Image Qualityhttps://modernod.com/news/nidek-launches-b-scan-denoising-software-with-deep-learning-to-enhance-oct-retinal-image-quality/2478684/Nidek has announced the launch of the B-scan Denoising Software for the Nidek OCT series. This software converts a B-scan retinal OCT image to a high definition image by a denoising technique using deep learnin